References
< Back

Characterize Cancer: Tissue Profiling¹

  • 741 genes for expanded genotyping

  • 47 promoter methylation genes

  • RNA-based fusion detection for a comprehensive view of
    common and rare fusions and splice isoforms

Guardant Infinity is for research use only. Not for diagnostic purposes.

Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.


CHARACTERIZE CANCER

Profile tumors to reveal current and emerging cancer biomarkers with our cutting-edge technology.

Characterize Cancer: Liquid Profiling¹

  • 755 genes for expanded genotyping

  • Methylation-based tumor fraction to quantify disease burden

Next >